glp 1 from china China's Hengrui/Kailera duo just filed an NDA for HRS9531: a dual GLP‑1/GIP agonist designed for long-term obesity treatment (not just diabetes). This strategy sets it apart other GLP‑1 drugs. What makes More Chinese biotechs challenge GLP-1
Pay in 4 interest-free payments of $6.09 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29







:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
















